Safety issues and prospects for future generations of PPAR modulators
作者： A RUBENSTRUNK , R HANF , D HUM , J FRUCHART , B STAELS
DOI: 10.1016/J.BBALIP.2007.02.003
关键词: Dyslipidemia 、 Peroxisome proliferator-activated receptor 、 Glucose homeostasis 、 PPAR agonist 、 Type 2 diabetes 、 Pharmacology 、 Side effect 、 Medicine 、 Adverse effect 、 Insulin resistance
摘要: … the nature of the side effect and the putative PPAR-related mechanism of action. This review … of PPAR agonists that could be of concern when considering the development of new PPAR …
elsevier.com
sci-hub.se 参考文章(199)
J. Cooper, J. N. Morris, M. F. Oliver, J. A. Heady, W.H.O. cooperative trial on primary prevention of ischaemic heart disease using clofibrate to lower serum cholesterol: mortality follow-up. The Lancet. pp. 379- 385 ,(1980)
Francois-Xavier Caroli-Bosc, Philippe Le Gall, Pascal Pugliese, Benoit Delabre, Corinne Caroli-Bosc, Jean-Francois Demarquay, Jean-Pierre Delmont, Patrick Rampal, J.C. Montet, Role of fibrates and HMG-CoA reductase inhibitors in gallstone formation: epidemiological study in an unselected population. Digestive Diseases and Sciences. ,vol. 46, pp. 540- 544 ,(2001) , 10.1023/A:1005643014395
K. W. Rumpf, M. Barth, M. Blech, H. Kaiser, I. Koop, R. Arnold, F. Scheler, Bezafibrat-induzierte Myolyse und Myoglobinurie bei Patienten mit eingeschränkter Nierenfunktion Journal of Molecular Medicine. ,vol. 62, pp. 346- 348 ,(1984) , 10.1007/BF01716252
D Einhorn, J Rosenstock, S Yu, K Hershon, N B Glazer, Efficacy and safety of pioglitazone in type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin therapy. International Journal of Clinical Practice. ,vol. 56, pp. 251- 257 ,(2002)
N el Esper, A Pruna, C Hottelart, J M Achard, A Fournier, [Fenofibrate increases blood creatinine, but does not change the glomerular filtration rate in patients with mild renal insufficiency]. Nephrologie. ,vol. 20, pp. 41- 44 ,(1999)
Bargman Jm, Lipscombe J, Lewis Gf, Cattran D, Deterioration in renal function associated with fibrate therapy. Clinical Nephrology. ,vol. 55, pp. 39- 44 ,(2001)
Blane Gf, Pinaroli F, [Fenofibrate: animal toxicology in relation to side-effects in man (author's transl)]. La Nouvelle presse médicale. ,vol. 9, pp. 3737- ,(1980)
Fred S Harman, Christopher J Nicol, Holly E Marin, Jerrold M Ward, Frank J Gonzalez, Jeffrey M Peters, Peroxisome proliferator–activated receptor-δ attenuates colon carcinogenesis Nature Medicine. ,vol. 10, pp. 481- 483 ,(2004) , 10.1038/NM1026
Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study The Lancet. ,vol. 357, pp. 905- 910 ,(2001) , 10.1016/S0140-6736(00)04209-4
Holly E. Marin, Marjorie A. Peraza, Andrew N. Billin, Timothy M. Willson, Jerrold M. Ward, Mary J. Kennett, Frank J. Gonzalez, Jeffrey M. Peters, Ligand activation of peroxisome proliferator-activated receptor β inhibits colon carcinogenesis Cancer Research. ,vol. 66, pp. 4394- 4401 ,(2006) , 10.1158/0008-5472.CAN-05-4277